DUSA PHARMACEUTICALS, INC.
NASDAQ : DUSA

DUSA PHARMACEUTICALS, INC.

March 13, 2007 14:24 ET

DUSA Pharmaceuticals, Inc. to Host Fourth Quarter and Full Year 2006 Financial Results and Corporate Highlights Conference Call

WILMINGTON, MASSACHUSETTS--(CCNMatthews - March 13, 2007) - DUSA Pharmaceuticals, Inc. (NASDAQ GM:DUSA) announces that its corporate highlights and year end financial results press release will be issued on Friday, March 16th at 6:30 a.m. to be followed by a conference call at 8:30 a.m.



Friday, March 16th - 8:30 a.m. Eastern
If calling from the US or Canada use the following toll-free number:
800.647.4314
Password - DUSA

For International callers use
641.297.7663

A recorded replay of the call will be available
North American callers 877.863.0350
International callers 858.244.1268


The call will be accessible on our web site approximately 1 hour following the call at www.dusapharma.com.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of pre-cancerous actinic keratoses, and is being developed for the treatment of acne. DUSA's other dermatology products include Nicomide®, and the AVAR® line. These products target patients with acne and rosacea. DUSA is also developing certain internal indications of Levulan PDT. DUSA is based in Wilmington, MA.

Contact Information

  • DUSA Pharmaceuticals, Inc.
    Shari Lovell
    Director, Shareholder Services
    (416) 363-5059
    Website: www.dusapharma.com